← MiniMed Group, Inc. Common Stock overview

MiniMed Group, Inc. Common Stock vs Beta Bionics, Inc. Common Stock: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

MiniMed Group, Inc. Common Stock (MMED)

Q3 2026
▲3

MiniMed Flex Launch Drives Strong Q1, Raised Outlook

  • MiniMed Flex pump launch MiniMed launched its smallest app-controlled insulin pump in the U.S. in June, with a new sensor and algorithm. The Flex drove new pump sales up over 20% and new prescribers up 24%, powering U.S. revenue growth to 13.1% from 1.5%.

    The Flex launch is the core new product driving MiniMed's accelerating growth and is the main reason the stock is moving.

  • Abbott sensor partnership expands Abbott began supplying its Instinct sensor for MiniMed's new pump in August, and the FDA approved Abbott's dual ketone-glucose monitor with an exclusive MiniMed integration for smart dosing. This broadens MiniMed's sensor options and strengthens its product ecosystem.

    The Abbott partnership is a new collaboration that enhances MiniMed's competitive position and future product pipeline.

  • Strong Q1 results and raised guidance MiniMed reported Q1 revenue of $843 million, up 15.8% organically, and raised full-year organic growth guidance to about 10.5%. The company narrowed its net loss to zero and reaffirmed its 16% adjusted EBITDA margin target, boosting investor confidence.

    The earnings beat and guidance raise are the key financial catalysts that directly lifted the stock price.

  • Profitability lags and hedge fund conviction weakens Despite strong revenue, adjusted EBITDA margin was only 9.9% and free cash flow was negative $90 million due to separation costs. Hedge fund holdings fell 18% in Q2, and short interest stands at 20.66% of float, signaling some caution.

    This is the main counterweight: profitability and cash flow are not yet keeping pace with revenue growth, and some investors are pulling back.

July 2026
▲3

MiniMed Flex Launch Drives Strong Q1, Raised Outlook

  • MiniMed Flex pump launch MiniMed launched its smallest app-controlled insulin pump in the U.S. in June, with a new sensor and algorithm. The Flex drove new pump sales up over 20% and new prescribers up 24%, powering U.S. revenue growth to 13.1% from 1.5%.

    The Flex launch is the core new product driving MiniMed's accelerating growth and is the main reason the stock is moving.

  • Abbott sensor partnership expands Abbott began supplying its Instinct sensor for MiniMed's new pump in August, and the FDA approved Abbott's dual ketone-glucose monitor with an exclusive MiniMed integration for smart dosing. This broadens MiniMed's sensor options and strengthens its product ecosystem.

    The Abbott partnership is a new collaboration that enhances MiniMed's competitive position and future product pipeline.

  • Strong Q1 results and raised guidance MiniMed reported Q1 revenue of $843 million, up 15.8% organically, and raised full-year organic growth guidance to about 10.5%. The company narrowed its net loss to zero and reaffirmed its 16% adjusted EBITDA margin target, boosting investor confidence.

    The earnings beat and guidance raise are the key financial catalysts that directly lifted the stock price.

  • Profitability lags and hedge fund conviction weakens Despite strong revenue, adjusted EBITDA margin was only 9.9% and free cash flow was negative $90 million due to separation costs. Hedge fund holdings fell 18% in Q2, and short interest stands at 20.66% of float, signaling some caution.

    This is the main counterweight: profitability and cash flow are not yet keeping pace with revenue growth, and some investors are pulling back.

Latest
▲3

MiniMed Flex Launch Drives Strong Q1, Raised Outlook

  • MiniMed Flex pump launch MiniMed launched its smallest app-controlled insulin pump in the U.S. in June, with a new sensor and algorithm. The Flex drove new pump sales up over 20% and new prescribers up 24%, powering U.S. revenue growth to 13.1% from 1.5%.

    The Flex launch is the core new product driving MiniMed's accelerating growth and is the main reason the stock is moving.

  • Abbott sensor partnership expands Abbott began supplying its Instinct sensor for MiniMed's new pump in August, and the FDA approved Abbott's dual ketone-glucose monitor with an exclusive MiniMed integration for smart dosing. This broadens MiniMed's sensor options and strengthens its product ecosystem.

    The Abbott partnership is a new collaboration that enhances MiniMed's competitive position and future product pipeline.

  • Strong Q1 results and raised guidance MiniMed reported Q1 revenue of $843 million, up 15.8% organically, and raised full-year organic growth guidance to about 10.5%. The company narrowed its net loss to zero and reaffirmed its 16% adjusted EBITDA margin target, boosting investor confidence.

    The earnings beat and guidance raise are the key financial catalysts that directly lifted the stock price.

  • Profitability lags and hedge fund conviction weakens Despite strong revenue, adjusted EBITDA margin was only 9.9% and free cash flow was negative $90 million due to separation costs. Hedge fund holdings fell 18% in Q2, and short interest stands at 20.66% of float, signaling some caution.

    This is the main counterweight: profitability and cash flow are not yet keeping pace with revenue growth, and some investors are pulling back.

Beta Bionics, Inc. Common Stock (BBNX)

Q3 2026
▼2▲1

Mint pump cleared, but dilution and guidance cut weigh on BBNX

  • Fair value cut on medtech valuation reset Analysts slashed Beta Bionics' fair value estimate to $19.80 from $31.30, citing slower revenue growth, thinner profit margins and a much lower assumed future P/E multiple. This reset reflects broad medtech sector headwinds and pulled the stock's perceived worth down, even as some banks raised targets.

    It explains the sharp drop in the stock's assessed value and the cautious backdrop for BBNX.

  • $125M stock offering dilutes shareholders Beta Bionics announced a $125 million public offering of new common stock, with an option for underwriters to buy up to $18.75 million more. Selling new shares dilutes existing owners' stakes and signals a need for cash, sending BBNX down 8% after hours.

    It is a direct, company-specific event that immediately pressures the share price through dilution.

  • Mint pump FDA clearance offset by 2026 revenue guidance cut Beta Bionics won FDA clearance for its Mint patch pump and submitted a next-gen dosing algorithm, key product milestones. But it cut 2026 revenue guidance to $121–$126 million from $131–$136 million, warning that some iLet customers may delay purchases before Mint launches. Shares jumped 15% on the news but remain down 27% year to date.

    It captures the central tension this period: a major product win versus a near-term sales shortfall.

  • New CGM partnerships expand iLet ecosystem Beta Bionics partnered with Senseonics to add Eversense 365 continuous glucose monitoring to its iLet platform, expected to launch in late 2026. Combined with Abbott's new dual glucose-ketone sensor gaining FDA authorization and planned iLet compatibility, these deals broaden the iLet's appeal and could support future demand.

    It shows concrete steps to strengthen the product ecosystem, a positive long-term driver for BBNX.

August 2026
▼2▲1

Mint pump cleared, but dilution and guidance cut weigh on BBNX

  • Fair value cut on medtech valuation reset Analysts slashed Beta Bionics' fair value estimate to $19.80 from $31.30, citing slower revenue growth, thinner profit margins and a much lower assumed future P/E multiple. This reset reflects broad medtech sector headwinds and pulled the stock's perceived worth down, even as some banks raised targets.

    It explains the sharp drop in the stock's assessed value and the cautious backdrop for BBNX.

  • $125M stock offering dilutes shareholders Beta Bionics announced a $125 million public offering of new common stock, with an option for underwriters to buy up to $18.75 million more. Selling new shares dilutes existing owners' stakes and signals a need for cash, sending BBNX down 8% after hours.

    It is a direct, company-specific event that immediately pressures the share price through dilution.

  • Mint pump FDA clearance offset by 2026 revenue guidance cut Beta Bionics won FDA clearance for its Mint patch pump and submitted a next-gen dosing algorithm, key product milestones. But it cut 2026 revenue guidance to $121–$126 million from $131–$136 million, warning that some iLet customers may delay purchases before Mint launches. Shares jumped 15% on the news but remain down 27% year to date.

    It captures the central tension this period: a major product win versus a near-term sales shortfall.

  • New CGM partnerships expand iLet ecosystem Beta Bionics partnered with Senseonics to add Eversense 365 continuous glucose monitoring to its iLet platform, expected to launch in late 2026. Combined with Abbott's new dual glucose-ketone sensor gaining FDA authorization and planned iLet compatibility, these deals broaden the iLet's appeal and could support future demand.

    It shows concrete steps to strengthen the product ecosystem, a positive long-term driver for BBNX.

Latest
▼2▲1

Mint pump cleared, but dilution and guidance cut weigh on BBNX

  • Fair value cut on medtech valuation reset Analysts slashed Beta Bionics' fair value estimate to $19.80 from $31.30, citing slower revenue growth, thinner profit margins and a much lower assumed future P/E multiple. This reset reflects broad medtech sector headwinds and pulled the stock's perceived worth down, even as some banks raised targets.

    It explains the sharp drop in the stock's assessed value and the cautious backdrop for BBNX.

  • $125M stock offering dilutes shareholders Beta Bionics announced a $125 million public offering of new common stock, with an option for underwriters to buy up to $18.75 million more. Selling new shares dilutes existing owners' stakes and signals a need for cash, sending BBNX down 8% after hours.

    It is a direct, company-specific event that immediately pressures the share price through dilution.

  • Mint pump FDA clearance offset by 2026 revenue guidance cut Beta Bionics won FDA clearance for its Mint patch pump and submitted a next-gen dosing algorithm, key product milestones. But it cut 2026 revenue guidance to $121–$126 million from $131–$136 million, warning that some iLet customers may delay purchases before Mint launches. Shares jumped 15% on the news but remain down 27% year to date.

    It captures the central tension this period: a major product win versus a near-term sales shortfall.

  • New CGM partnerships expand iLet ecosystem Beta Bionics partnered with Senseonics to add Eversense 365 continuous glucose monitoring to its iLet platform, expected to launch in late 2026. Combined with Abbott's new dual glucose-ketone sensor gaining FDA authorization and planned iLet compatibility, these deals broaden the iLet's appeal and could support future demand.

    It shows concrete steps to strengthen the product ecosystem, a positive long-term driver for BBNX.